Neurocrine Biosciences Presents INGREZZA® (valbenazine)

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society 2023 Annual Congress

SAN DIEGO, May 15, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. today announced findings from a post hoc analysis of two long-term studies of INGREZZA® capsules evaluating global tardive... | May 15, 2023

Related Keywords

Canada , Calgary , Alberta , Toronto , Ontario , Eiryw Roberts , Neurocrine Biosciences , Prnewswire Neurocrine Biosciences Inc , Exchange Commission , Neurocrine Biosciences Inc , Nasdaq , Facebook , Schizophrenia International Research Society , Linkedin , Twitter , Clinical Global Impression , Change Tardive Dyskinesia , Patient Global Impression , Negative Syndrome Scale , Calgary Depression Scale , Chief Medical Officer , Tardive Dyskinesia , All Rights , Nc Stock Exchange , News , Information , Press Release , Han , Bay , 023 , Neurocrine , Oday , Nnounced , Findings , Rom , Most , Oc , Analysis , F , Two , Studies , Capsules , Valuating , Lobal Nbix Us64125c1099 ,